Testosterone (TRT) + HCG: The Endocrine Support Stack

What this stack does

Testosterone (TRT) replaces endogenous testosterone when the body's own output has fallen below functional levels. Exogenous testosterone binds androgen receptors across muscle, bone, neural tissue, and the cardiovascular system, restoring hormonal signalling that governs recovery, libido, body composition, mood stability, and red blood cell production. The mechanism is direct: you are supplying the hormone the testes are no longer producing in sufficient quantity.

The problem is that exogenous testosterone signals the hypothalamic-pituitary-gonadal (HPG) axis to shut down its own output. The hypothalamus reduces gonadotropin-releasing hormone (GnRH) pulse frequency, the pituitary stops secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the testes go dormant. Testicular atrophy follows. Intratesticular testosterone, which is required for spermatogenesis, collapses. For men who care about fertility or the long-term integrity of gonadal tissue, this suppression is the central clinical problem with TRT monotherapy.

HCG (human chorionic gonadotropin) is an LH analogue. It binds the LH receptor on Leydig cells and stimulates local testosterone production inside the testes, bypassing the suppressed pituitary signal. Used alongside exogenous testosterone, HCG keeps intratesticular testosterone at a level that supports spermatogenesis and prevents significant testicular atrophy. Research in this area is established: studies including work by Coviello et al. (2005) demonstrate that co-administration of HCG during testosterone therapy preserves intratesticular testosterone concentrations that would otherwise collapse under suppression.

Who it's for

This stack is relevant if you are already on or considering testosterone replacement and want to preserve testicular function during treatment. That includes men who intend to have children, men who want to maintain the option of fertility without committing to a timeline, and men who have noticed testicular atrophy on TRT monotherapy and want to reverse or prevent further progression.

It is also relevant if you have experienced the downstream effects of full HPG axis suppression: reduced scrotal warmth, testicular volume loss, or a sense that something has been switched off below the surface. These are not cosmetic concerns. Leydig cell health and intratesticular steroidogenesis matter beyond fertility, and some men report subjective differences in energy and libido when HCG is added, though the evidence on these subjective effects is largely anecdotal.

This is not a stack for men seeking to use HCG as a standalone protocol or as a bridge between testosterone courses. The protocol here is concurrent use: both compounds running together, with the goal of endocrine support rather than acute hormonal elevation.

The protocol

Testosterone (TRT)

• Dose: 100-200mg per week, total weekly dose divided across injections
• Form: Testosterone cypionate or testosterone enanthate (injectable); testosterone undecanoate or transdermal gel are alternatives, but injectable esters are the standard for protocols where HCG is co-administered
• Frequency: Twice weekly (e.g. Monday and Thursday) to maintain stable serum levels and minimise peak-to-trough fluctuation
• Route: Subcutaneous or intramuscular injection
• Timing: No fixed food requirement; consistent day-of-week timing matters more than time of day

HCG

• Dose: 250-500 IU per injection
• Frequency: Two to three times per week; many clinicians align HCG injections with testosterone injection days
• Route: Subcutaneous injection
• Timing: Can be administered at the same time as testosterone, using separate syringes and separate injection sites

Cycle and washout

TRT is typically an indefinite protocol, not a time-limited course. HCG is run concurrently for as long as fertility preservation or testicular function is a priority. If fertility is the primary goal, FSH monitoring is warranted every 3-6 months. If you are pausing TRT for any reason, HCG alone can serve as a bridge to support endogenous recovery, but the timeline for HPG axis restoration varies significantly between individuals and depends on duration of prior suppression.

What to expect, week by week

Side effects and safety

Testosterone (TRT) risks: Erythrocytosis (elevated haematocrit) is the most clinically significant risk with long-term testosterone use, and requires regular monitoring. Elevated oestradiol from aromatisation can produce water retention, nipple sensitivity, or mood changes in susceptible men; aromatase inhibitor use is sometimes considered but is not universally recommended and carries its own risks. Acne and accelerated hair loss in genetically predisposed men are common androgenic effects. Exogenous testosterone suppresses sperm production when used without HCG; this effect is the central rationale for the combination protocol described here.

HCG risks: HCG can increase oestradiol through stimulation of Leydig cell aromatase activity; in some men, adding HCG to TRT elevates oestradiol further, which may require monitoring and occasional management. Injection site reactions are possible but generally mild. At high doses, HCG can cause fluid retention. Prolonged use at high doses is not without risk, and there is some evidence that Leydig cell desensitisation can occur with continuous high-dose HCG use; this is a reason to keep HCG doses conservative (250-500 IU) rather than using the higher doses sometimes seen in post-TRT recovery protocols.

Combined risks: The primary combined risk is oestradiol elevation from two independent aromatase-stimulating signals. Monitoring oestradiol at baseline and at the week 8-12 lab draw is advisable. Drug interactions are not a major concern for most men, but those taking anticoagulants should be aware that testosterone can affect clotting parameters.

Prescription status: Both Testosterone (TRT) and HCG are prescription medications in most jurisdictions. Access to these compounds should be via a qualified clinician who can provide baseline labs, ongoing monitoring, and dose adjustments. Self-administering exogenous testosterone or HCG without medical oversight removes the safety net that monitoring provides and is not advisable.

Sourcing and quality

Both compounds in this stack are prescription pharmaceuticals. Pharmaceutical-grade testosterone (testosterone cypionate or enanthate) and pharmaceutical-grade HCG are manufactured under GMP conditions and carry a level of purity assurance that research-grade or grey-market products do not reliably match. Obtaining these compounds through a licensed prescribing physician or licensed compounding pharmacy is the standard of care in most markets, and it is the context in which the dosing protocols described above were developed.

If you are working with compounded testosterone or compounded HCG, the key quality markers are: clarity of the solution (no particulate matter, no cloudiness unless the formulation specifies otherwise), confirmed concentration on the vial label, and sourcing from a pharmacy with documented sterility testing. For HCG specifically, reconstitution from lyophilised powder is standard; bacteriostatic water is the correct diluent, not sterile water, as bacteriostatic water extends usable shelf life after reconstitution. Use the reconstitution calculator to confirm your diluent volumes and final concentration before drawing your first dose. Reconstituted HCG should be stored refrigerated and used within 30 days; beyond that, potency degrades.